In multiple myeloma (MM), MSCs from patients show altered osteogenic differentiation potential, increased secretion of pro-inflammatory cytokines such as IL-6 and CCL2, and enhanced support for tumor growth. This evidence concerns the gene CCL2 and plasma cell myeloma.